1 Continuing Medical Education and Industry Sponsorship The Pharma, Biotech and Device Colloquium Princeton, NJ June 7, 2005 Julie K. Taitsman, M.D., J.D.

Slides:



Advertisements
Similar presentations
Introduction to Existing State Disclosure Laws and Regulations Summit on Disclosure, Transparency and Aggregate Spend For Drug, Device and Biotech Companies.
Advertisements

Fair Market Value and Payments to Healthcare Professionals – How Should We Determine What We Pay? © Huron Consulting Services LLC. All rights reserved.
Professional Education Support Wyeth Pharmaceuticals Melinda Somasekhar, PhD.
Continuing Professional Development Conflict of Interest This presentation has been developed by the COI Working Group to assist in the implementation.
© 2009 Cengage Learning. All Rights Reserved. Healthcare Fraud and Abuse.
Marketing to Doctors – Payments for Loyalty Julie Brill Assistant Attorney General Vermont Attorney General ’ s Office Montpelier,
Sales & Marketing Compliance Training
Furnishing Your Compliance House: OIG Risk Areas Marie C. Infante, Sr. VP, Chief Compliance Officer, Golden Living & Affiliated Companies Ken Burgess,
Medicare Parts C and D Fraud, Waste, and Abuse Compliance Training
Lori K. Nomura | AWPHD Administrator’s Only Retreat Trends in Hospital/Physician Relations and Corporate Compliance May 22-24,
2005 FPMP Compliance Training: Physician/Hospital Financial Arrangements Presented by: Brigid M. Maloney, Esq. Brigid M. Maloney, Esq. U.B. Associates.
Compliance Requirements for the Pharmaceutical Industry and Impact on Marketing Practices Timothy M. Cunniff, Pharm.D. Vice President, Global Regulatory.
May 13, 2005 North Carolina State University Off-Label Use and Product Liability: Basic Principles David L. Baumer, Ph.D., J.D., Attorney at Law, Professor.
Clinical Compliance Programs: Investigator Payments, GCPs, and More…. Teri Crouse, J.D. Director of Compliance for Healthcare & Marketing.
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Compliance Best Practices in a Post Orthopedic Environment David Matyas.
Healthcare Referral Sources Legal Issues & Policy Recommendations Health Care Compliance Association Compliance Institute Anne M. Haule New Orleans, Louisiana.
Physician Preference Items: A New Paradigm By John M. McGuire President & CEO Surgical Implant Services, LLC.
August, 2005 Slide 1 MANAGING RISKS OF OFF-LABEL PROMOTION AND CONTINUING MEDICAL EDUCATION The FDA Regulatory and Compliance Symposium Annenberg Hall.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
Medicare Advantage & Part D Compliance Training 2009.
1 OPERATIONALIZING THE GUIDANCE A. Implementation where resources or culture may present resistance B.Some structural issues C. Specific marketing practices.
Presented by Claudia Schlosberg, Partner Blank Rome, LLP 600 New Hampshire Avenue, N.W. Washington, D.C
Restrictions on Referrals v Federal law prohibits referrals among providers that have tainted financial relationships v Any arrangement that confers an.
Legal Issues in Hospital- Hospice (and Other) Partnerships Brooke Bumpers, Esq. Hogan & Hartson, LLP Washington, D.C. October 12, 2002.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
OIG COMPLIANCE GUIDANCE FOR PHYSICIAN PRACTICES Washington County Hospital Association, Inc. CME Program October 26, 2000.
New Staff Orientation: Industry Relations Emory School of Medicine Zainab R. Wurie, JD July 15, 2014.
Blue Cross of Idaho Medicare Advantage Provider Fraud, Waste and Abuse Training Fall 2009.
CORPORATE COMPLIANCE PROGRAM The Office of Corporate Integrity
Pharmaceutical Regulatory & Compliance Congress Washington, DC November 9, 2006 Fair Market Value Considerations in Industry Relationships Wendy C. Goldstein,
DEPARTMENT OF MANAGEMENT SERVICES OFFICE OF INSPECTOR GENERAL.
1 Strategies for a Compliant Grant Process CIA Monitoring Obligations A. Monica Jonhart Director-U S Pharmaceuticals Compliance Bristol-Myers Squibb.
Medicare and Patient Assistance Sean M. Dougherty Senior Director Medicare Strategy & Patient Assistance Programs Government, Public Policy And Managed.
Sales and Marketing in the Pharmaceutical Industry: At the Vortex of the Perfect Legal Storm Paul E. Kalb, M.D., J.D. Princeton, N.J. - June 7, 2004.
Pharmaceutical Compliance Congress Washington, DC June 9, 2003 The HHS OIG Guidance: An In-Depth Analysis of Risk Areas Panelists: Patrick Davish, Merck.
Vendor Relations Policy. Why Is There A Policy? The Patient Protection and Affordable Care Act was signed into law March 23, The new law contains.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
KEY ENFORCEMENT ISSUES - The Government's Perspective Kathleen Meriwether Assistant United States Attorney Eastern District of Pennsylvania UNITED STATES.
WHAT STAKEHOLDERS NEED TO KNOW ABOUT THE CME/SUNSHINE ACT PROVISION OF THE ‘21 ST CENTURY CURES ACT’ JULY 14,
+ Role of Industry in Clinical Care, Research, and Education.
Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.
An Educational Session on HSC OP 10.27, Health Care Vendor Interactions April 20, 2009.
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
Agenda for Session Compliance in Clinical Research
Welcome….!!! CORPORATE COMPLIANCE PROGRAM Presented by The Office of Corporate Integrity 1.
1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.
National Medical Device Audioconference: How the Recent Landmark $311 Million Device Settlements Will Change Industry Practices Insights Into Federal Investigations.
Welcome General Compliance Training.  To inform you who to contact to ask questions  To let you know that you are responsible to disclose  To share.
ROPES & GRAY LLP The Compliance Environment and Grant Process: Oversight and Response in the Pharmaceutical Industry Howard L. Dorfman December 9, 2008.
California’s New Compliance Law Kelly N. Reeves
Enforcement Trends in the Pharmaceutical Industry Lewis Morris Chief Counsel Office of Inspector General, DHHS.
Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb,
0 Delegation of Services & Co-management The Co-management Dilemma.
The Growing Role of HHS-IG/DOJ, & Whistleblowers, In Drug Marketing Policy John F. Kamp August 25, 2005.
2016 ICAHN COMPLIANCE OFFICER WORKSHOP Stuart J. Vogelsmeier, J.D. May 26, 2016.
Chapter 4 The Legal and Regulatory Environment of Health Care.
Compliance and Enforcement Roundtable Discussion
HEALTH INFORMATION TECHNOLOGY SUMMIT OCTOBER 23, 2004 COMMUNITY-BASED COLLABORATIONS: LEGAL ISSUES: STARK, FRAUD & ABUSE Paul T. Smith, Esq. Partner,
Action Items: Monitoring Off-Label Promotion Do’s and Don’t’s
Tamara V. Scoville, Esq. Reed Smith LLP
Complying with FDA/OIG Rules
PHARMA AUDIOCONFERENCE An Analysis of the HHS OIG Draft Compliance Program Guidance for the Pharmaceutical Industry Overview of Draft CPG Michael P.
Medical Device Industry Update Overview of the Stark Laws
Brussels, June 6, 2007 Paul E. Kalb, M.D., J.D.
California’s “Comprehensive Compliance Program” Law
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
Implementing Controls Around Grants, Consulting Agreements, CME, Preceptorships, and Other Promotional Practices Paul E. Kalb Heidi C. Chen Fourth Annual.
National Health Information Technology Audioconference
Legal Issues in Getting Communities Connected
Presentation transcript:

1 Continuing Medical Education and Industry Sponsorship The Pharma, Biotech and Device Colloquium Princeton, NJ June 7, 2005 Julie K. Taitsman, M.D., J.D. Senior Counsel Industry Guidance Branch Office of Counsel to the Inspector General

2 The Anti-Kickback Statute Section 1128B(b) of the Social Security Act Criminal statute Prohibits purposeful payments, made directly or indirectly, to induce or reward the referral of items or services payable by Federal health care programs

3 The Anti-Kickback Statute Remuneration Offered, paid, solicited, or received To induce or reward Federal business Knowingly and willfully

4 The Anti-Kickback Statute “Arranging for or recommending” One purpose test Penalties: –Criminal –Civil –Administrative

5 Why Kickbacks Harm the Health Care System Overutilization Increased program cost Improper steering Unfair competition Systemic corruption

6 Ways Industry Sponsors Educational Activities Industry-run programs Grants to for-profit CME providers Grants to academic institutions Grants to professional organizations

7 Types of Kickbacks From drug or device manufacturer –to CME provider –directly to physician –indirectly to physician

8 OIG’s CPG for Pharmaceutical Manufacturers: CME Risk Areas Funding based on referral levels Sham education projects Funding conditioned on content or faculty of an educational program Manufacturer influence over the presenter of an educational program Violation of FDA rules

9 CPG Recommendations Separate grant making functions from sales and marketing Establish objective criteria that do not take into account the volume or value of referrals No manufacturer control over the speaker or content of the educational activity Bona fide educational purpose Documentation and regular monitoring

10 OIG’s CPG for Pharmaceutical Manufacturers: “Consultants” Risk Areas Sham consulting arrangements Payments for physicians to attend conferences in a passive capacity Payments for promotional activities Ghost written papers or speeches Gifts and gratuities

11 “Consultants” Recommendations Fair market value payments for reasonable, necessary, legitimate services Safe harbor whenever possible Disclose potential conflicts of interest Documentation

12 Conclusion Educational activities are important Funding must be accomplished in a fashion that is free from fraud and abuse Additional information is available on our website at